(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Bad flu season getting worse; skyrocketing cases set state record - 26 Web-based Course Stages for Successful Learning and Educating
- 3Aluminum salts emerge as likely target as health officials scrutinize childhood vaccines
- 4Flu season is underway. What are common symptoms to watch for?
- 5Instructions to Really Oversee Unsold SUVs in the Auto Business
- Cases of norovirus are on the rise just in time for the holiday season
- 5 Most Expected Film Delivery
- Protester climbs on to balcony of Iranian embassy in London
- Exposure to neighborhood violence leads some Denver teens to use tobacco and alcohol earlier, new study shows
- The most effective method to Redesign the Sound Framework in Your Smash 1500.
- Step by step instructions to Get a good deal on Your Rooftop Substitution Venture
- IDF says up to 90% of Iran’s weapons industry could be hit within days
- I traveled to 13 countries in 2025. This small island nation surprised me the most.
- Kids who get 2-month vaccines on time 7 times more likely to receive MMR shot: Study
